Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ADCT |
---|---|---|
09:32 ET | 11034 | 2.04 |
09:33 ET | 9895 | 2.045 |
09:35 ET | 29743 | 2.05 |
09:37 ET | 1487 | 2.051 |
09:39 ET | 6450 | 2.03 |
09:42 ET | 65416 | 2.1 |
09:44 ET | 20941 | 2.1099 |
09:46 ET | 45478 | 2.14 |
09:48 ET | 3231 | 2.1499 |
09:50 ET | 7077 | 2.16 |
09:51 ET | 1100 | 2.16 |
09:53 ET | 2590 | 2.15 |
09:55 ET | 4556 | 2.16 |
09:57 ET | 8998 | 2.22 |
10:00 ET | 56091 | 2.2973 |
10:02 ET | 8227 | 2.256 |
10:04 ET | 6951 | 2.25 |
10:06 ET | 9147 | 2.25 |
10:08 ET | 31457 | 2.315 |
10:09 ET | 14830 | 2.3218 |
10:11 ET | 12470 | 2.33 |
10:13 ET | 7129 | 2.4 |
10:15 ET | 75171 | 2.4294 |
10:18 ET | 25634 | 2.4591 |
10:20 ET | 13556 | 2.49 |
10:22 ET | 102571 | 2.56 |
10:24 ET | 60659 | 2.6301 |
10:26 ET | 133215 | 2.625 |
10:27 ET | 130469 | 2.63 |
10:29 ET | 141521 | 2.56 |
10:31 ET | 41391 | 2.59 |
10:33 ET | 42843 | 2.68 |
10:36 ET | 85718 | 2.61 |
10:38 ET | 48922 | 2.6301 |
10:40 ET | 35726 | 2.6493 |
10:42 ET | 29066 | 2.6496 |
10:44 ET | 49219 | 2.665 |
10:45 ET | 148200 | 2.7888 |
10:47 ET | 94038 | 2.65 |
10:49 ET | 27081 | 2.6125 |
10:51 ET | 131886 | 2.5088 |
10:54 ET | 53060 | 2.53 |
10:56 ET | 22601 | 2.5312 |
10:58 ET | 14470 | 2.57 |
11:00 ET | 18737 | 2.55 |
11:02 ET | 41751 | 2.62 |
11:03 ET | 45881 | 2.58 |
11:05 ET | 13529 | 2.57 |
11:07 ET | 8489 | 2.575 |
11:09 ET | 25558 | 2.61 |
11:12 ET | 59747 | 2.605 |
11:14 ET | 14621 | 2.59 |
11:16 ET | 70784 | 2.61 |
11:18 ET | 66231 | 2.615 |
11:20 ET | 44575 | 2.66 |
11:21 ET | 26376 | 2.64 |
11:23 ET | 61464 | 2.655 |
11:25 ET | 38133 | 2.69 |
11:27 ET | 36396 | 2.6505 |
11:30 ET | 47990 | 2.6909 |
11:32 ET | 26423 | 2.67 |
11:34 ET | 45670 | 2.7 |
11:36 ET | 69734 | 2.735 |
11:38 ET | 88911 | 2.765 |
11:39 ET | 62496 | 2.73 |
11:41 ET | 93637 | 2.7 |
11:43 ET | 35016 | 2.785 |
11:45 ET | 96568 | 2.8195 |
11:48 ET | 108096 | 2.74 |
11:50 ET | 69393 | 2.68 |
11:52 ET | 52281 | 2.77 |
11:54 ET | 15451 | 2.72 |
11:56 ET | 24877 | 2.74 |
11:57 ET | 39962 | 2.6851 |
11:59 ET | 158157 | 2.77 |
12:01 ET | 13094 | 2.7302 |
12:03 ET | 48483 | 2.7369 |
12:06 ET | 6767 | 2.69 |
12:08 ET | 45864 | 2.7697 |
12:10 ET | 93075 | 2.89 |
12:12 ET | 48856 | 2.845 |
12:14 ET | 65491 | 2.7645 |
12:15 ET | 60520 | 2.82 |
12:17 ET | 29239 | 2.7934 |
12:19 ET | 10589 | 2.79 |
12:21 ET | 73307 | 2.79 |
12:24 ET | 30117 | 2.7707 |
12:26 ET | 4554 | 2.78 |
12:28 ET | 30747 | 2.7301 |
12:30 ET | 23350 | 2.76 |
12:32 ET | 13202 | 2.78 |
12:33 ET | 16471 | 2.7485 |
12:35 ET | 6904 | 2.722 |
12:37 ET | 40513 | 2.74 |
12:39 ET | 9846 | 2.76 |
12:42 ET | 12431 | 2.77 |
12:44 ET | 6342 | 2.755 |
12:46 ET | 8809 | 2.766 |
12:48 ET | 18416 | 2.76 |
12:50 ET | 2180 | 2.752 |
12:51 ET | 49908 | 2.715 |
12:53 ET | 54920 | 2.78 |
12:55 ET | 14098 | 2.8 |
12:57 ET | 5698 | 2.815 |
01:00 ET | 40963 | 2.84 |
01:02 ET | 21377 | 2.85 |
01:04 ET | 25274 | 2.86 |
01:06 ET | 75997 | 2.87 |
01:08 ET | 101272 | 2.8992 |
01:09 ET | 93343 | 2.9988 |
01:11 ET | 249734 | 3.1215 |
01:13 ET | 231382 | 3.0201 |
01:15 ET | 223625 | 2.85 |
01:18 ET | 189808 | 2.86 |
01:20 ET | 133910 | 2.8 |
01:22 ET | 119055 | 2.851 |
01:24 ET | 7137 | 2.8499 |
01:26 ET | 43665 | 2.9001 |
01:27 ET | 36459 | 2.8706 |
01:29 ET | 45558 | 2.84 |
01:31 ET | 18511 | 2.83 |
01:33 ET | 5676 | 2.845 |
01:36 ET | 37700 | 2.82 |
01:38 ET | 5996 | 2.82 |
01:40 ET | 14126 | 2.83 |
01:42 ET | 5205 | 2.8212 |
01:44 ET | 7393 | 2.81 |
01:45 ET | 12962 | 2.84 |
01:47 ET | 19009 | 2.85 |
01:49 ET | 2105 | 2.849 |
01:51 ET | 18590 | 2.875 |
01:54 ET | 9900 | 2.88 |
01:56 ET | 17342 | 2.8819 |
01:58 ET | 6036 | 2.89 |
02:00 ET | 20242 | 2.9 |
02:02 ET | 86833 | 2.95 |
02:03 ET | 72337 | 2.8797 |
02:05 ET | 34992 | 2.9015 |
02:07 ET | 15408 | 2.94 |
02:09 ET | 22295 | 2.906 |
02:12 ET | 14797 | 2.91 |
02:14 ET | 21077 | 2.902 |
02:16 ET | 7523 | 2.93 |
02:18 ET | 23364 | 2.96 |
02:20 ET | 30124 | 2.9735 |
02:21 ET | 16938 | 2.9711 |
02:23 ET | 20423 | 2.95 |
02:25 ET | 59621 | 2.86 |
02:27 ET | 32736 | 2.91 |
02:30 ET | 1598 | 2.9007 |
02:32 ET | 19352 | 2.9 |
02:34 ET | 9600 | 2.89 |
02:36 ET | 44529 | 2.84 |
02:38 ET | 4898 | 2.84 |
02:39 ET | 17165 | 2.87 |
02:41 ET | 49306 | 2.91 |
02:43 ET | 15361 | 2.9376 |
02:45 ET | 43353 | 2.9564 |
02:48 ET | 24359 | 2.94 |
02:50 ET | 12920 | 2.95 |
02:52 ET | 2518 | 2.9505 |
02:54 ET | 1678 | 2.95 |
02:56 ET | 20525 | 2.96 |
02:57 ET | 27610 | 2.9401 |
02:59 ET | 11423 | 2.96 |
03:01 ET | 87093 | 2.99 |
03:03 ET | 10378 | 2.99 |
03:06 ET | 11927 | 2.99 |
03:08 ET | 11789 | 3.0004 |
03:10 ET | 9205 | 3.0096 |
03:12 ET | 3854 | 2.99 |
03:14 ET | 12342 | 3 |
03:15 ET | 23311 | 3.0283 |
03:17 ET | 14019 | 3.02 |
03:19 ET | 25345 | 3.018 |
03:21 ET | 11747 | 3 |
03:24 ET | 9381 | 3.02 |
03:26 ET | 33782 | 3.005 |
03:28 ET | 10964 | 3.01 |
03:30 ET | 48702 | 2.98 |
03:32 ET | 44949 | 2.9502 |
03:33 ET | 14319 | 2.982 |
03:35 ET | 26705 | 3.02 |
03:37 ET | 28051 | 3.035 |
03:39 ET | 46256 | 3.0699 |
03:42 ET | 57931 | 3.1 |
03:44 ET | 77891 | 3.15 |
03:46 ET | 91857 | 3.07 |
03:48 ET | 141294 | 3.01 |
03:50 ET | 40288 | 3.015 |
03:51 ET | 36428 | 3.0512 |
03:53 ET | 34570 | 3.105 |
03:55 ET | 40206 | 3.105 |
03:57 ET | 61523 | 3.111 |
04:00 ET | 201926 | 3.13 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
ADC Therapeutics SA | 302.6M | -1.3x | --- |
Personalis Inc | 293.2M | -2.5x | --- |
Fate Therapeutics Inc | 301.8M | -1.6x | --- |
Cidara Therapeutics Inc | 259.6M | -0.9x | --- |
Codexis Inc | 384.9M | -5.4x | --- |
SAGE Therapeutics Inc | 343.2M | -1.0x | --- |
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $302.6M |
---|---|
Revenue (TTM) | $70.7M |
Shares Outstanding | 96.7M |
ADC Therapeutics SA does not pay a dividend. | |
Beta | 1.52 |
EPS | $-2.40 |
Book Value | $-1.80 |
P/E Ratio | -1.3x |
Price/Sales (TTM) | 4.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -195.42% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.